Drug Safety Update
March 2022: Cladribine (Mavenclad): new advice to minimise risk of serious liver injury
January 2021: Fingolimod (Gilenya▼): updated advice about the risks of serious liver injury and herpes meningoencephaliti
January 2021: Dimethyl fumarate (Tecfidera): updated advice on the risk of progressive multifocal leukoencephalopathy (PML) associated with mild lymphopenia
February 2020: Lemtrada▼ (alemtuzumab): updated restrictions and strengthened monitoring requirements following review of serious cardiovascular and immune-mediated reactions
September 2019: Fingolimod (Gilenya▼): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception
December 2017: Fingolimod (Gilenya▼): updated advice about risk of cancers and serious infections
December 2017: Fingolimod (Gilenya▼): new contraindications in relation to cardiac risk
April 2017: Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy
April 2016: Fingolimod (Gilenya▼): risks of progressive multifocal leukoencephalopathy, basal-cell carcinoma, and opportunistic infections
April 2016: Natalizumab (Tysabri▼): progressive multifocal leukoencephalopathy—updated advice to support early detection
December 2014: Natalizumab (Tysabri▼): risk of progressive multifocal leukoencephalopathy increases after 2 years of therapy
Prescribe by brand, as there can be variation in the licensing of different brands containing the same drug.
